SERDs in Breast Cancer at ASCO 2024

CE / CME

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 18, 2024

Expiration: June 17, 2025

Aditya Bardia
Aditya Bardia, MD, MPH, FASCO
Virginia Kaklamani
Virginia Kaklamani, MD, DSc
Sarah L. Sammons
Sarah L. Sammons, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Presurvey 1: Which of the following would be the best next step for a patient with breast cancer progression on a CDK4/6 inhibitor + an aromatase inhibitor?

2.

Presurvey 2: For patients with breast cancer with disease progression on CDK4/6i + ET, which mutation would make them candidates for an approved oral selective estrogen receptor degrader?

3.

Patient Case Example



  • A 46-yr-old woman underwent lumpectomy in left breast with 3.2-cm tumor that was found to be ER 90%, PgR 30%, and HER2 1+

    • SLN was found to be negative

    • Oncotype score was 16



  • She completed 5 yr of adjuvant tamoxifen and then at 6 yr from diagnosis was found to have bone metastases

    • Biopsy showed ER 60%, PgR 30%, HER2 1+ breast cancer



  • She started on ribociclib plus OFS and letrozole, but 2 yr afterwards is experiencing disease progression

Presurvey 3: NGS testing shows an ESR1 mutation. What treatment would you recommend now?

4.

Presurvey 4: Your patient has been receiving elacestrant for 1 mo and develops grade 2 hyperlipidemia. Which of the following is the most appropriate strategy for managing hyperlipidemia with an oral SERD therapy?

5.

Presurvey 5: How confident are you in your ability to implement strategies to promote adherence to and persistence with oral SERD therapy?